At this year’s ASCRS conference in Boston, Massachusetts, we spoke with Dr. Nir Shoham Hazon. He is the director of the Miramichi EyeNB Center of Excellence in New Brunswick, Canada.in a conversation with Ophthalmology Times EuropeDr. Shoham Hazon provided highlights from two paper presentations.
Editor’s note: The following transcript has been lightly edited for clarity.
Hello, my name is Nir Shoham Hazon. I’m a glaucoma and advanced anterior segment surgeon, and she’s from Miramichi, New Brunswick, Canada, and she’s the director of the Miramichi EyeNB Center of Excellence. We were in Boston for her ASCRS and presented his two papers on behalf of Nova Eye’s iTrack microcatheter. My first paper addressed drug burden in patients with primary open-angle glaucoma who are taking three or more medications. What we observed over 12 months was that at baseline the patient’s IOP was his 20, but at the 12 month follow-up his IOP was in his mid-teens. is. Focusing on drug burden, most patients were on 3.5 her medications and he was on 2.5 at the end of follow-up.
In terms of glaucoma severity, most patients had mild disease. Also focusing on the safety and efficacy of this procedure, the drug burden was significantly reduced to his 2.5 reduction class. Some patients were taking oral carbonic anhydrase preoperatively but stopped taking it postoperatively, and the last follow-up was 12 months. She had one patient who had transient emphysema, but this was a very special group of patients, so two of her patients, representing about 1%, required further filtration surgery. It was necessary. Overall, the safety and efficacy of Nova Eye’s iTrack microcatheter was demonstrated in this very unique patient group.
The second paper I published was on the safety and efficacy of Nova Eye’s iTrack microcatheter in patients with primary angle-closure glaucoma. This was a unique paper that investigated 47 eyes and examined the safety and efficacy of mixed surgery in patients with primary angle closure. Traditionally, primary angle-closure glaucoma is treated with laser peripheral iridotomy, followed by filtration surgery if intraocular pressure is not controlled. Minimally invasive glaucoma surgery is currently available in the treatment of primary angle-closure glaucoma, which is safe and effective. 47 patients in our cohort underwent iTrack canaloplasty Ab-interno either as a stand-alone procedure or in combination with cataract surgery.
What we observed in the entire group was that preoperative IOP was approximately 20 millimeters of mercury and in the postoperative combination group it was approximately mid-teens. However, when we divided the group into control and non-control groups, we found that the non-control group’s baseline IOP was actually 25, and his post-operative IOP was in his early teens, or about 12. got it. Dosage was significantly reduced. It puts a strain on your eyes. His case of transient anteroloboma. In conclusion, canaloplasty Ab-interno using Nova Eye’s iTrack microcatheter was safe and effective in patients requiring cataract and glaucoma procedures.
